Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Estrella Immunopharma ( (ESLA) ) has issued an announcement.
On August 1, 2025, Estrella Immunopharma received a notice from Nasdaq indicating non-compliance with the minimum Market Value of Listed Securities requirement of $35,000,000, which was not met from June 13 to July 31, 2025. The company has 180 days to regain compliance, with plans to actively monitor its market value and explore options to meet Nasdaq’s listing requirements, though there is no assurance of success.
The most recent analyst rating on (ESLA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Estrella Immunopharma stock, see the ESLA Stock Forecast page.
More about Estrella Immunopharma
Estrella Immunopharma, Inc. operates in the biotechnology industry, focusing on developing innovative immunotherapy solutions. The company is primarily engaged in creating treatments for various diseases, leveraging advanced technologies to enhance patient outcomes.
Average Trading Volume: 181,446
Technical Sentiment Signal: Sell
Current Market Cap: $30.74M
For a thorough assessment of ESLA stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money